𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Comment on ‘Impact of CYP2D6*10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy’

✍ Scribed by Timothy L. Lash; Thomas P. Ahern; Deirdre Cronin-Fenton; Jens Peter Garne; Stephen Hamilton-Dutoit; Henrik Toft Sørensen

Book ID
108584246
Publisher
John Wiley and Sons
Year
2008
Tongue
English
Weight
56 KB
Volume
99
Category
Article
ISSN
1347-9032

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Prognostic factors of early distant recu
Prognostic factors of early distant recurrence in hormone receptor-positive, postmenopausal breast cancer patients receiving adjuvant tamoxifen therapy : Results of a retrospective analysis
✍ Marc Debled; Gaëtan MacGrogan; Véronique Brouste; Simone Mathoulin-Pelissier; Mi 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 99 KB 👁 1 views

## Abstract ## BACKGROUND Current adjuvant hormone therapy in postmenopausal women with breast cancer is debatable between upfront aromatase inhibitors (AIs) and sequential treatment with tamoxifen. A major concern is the higher rate of early recurrences observed with sequential treatment. The aut

Genetic polymorphisms of CYP2D6*10 and C
Genetic polymorphisms of CYP2D6*10 and CYP2C19*2, *3 are not associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifen
✍ Matthew Goetz; Vera Suman 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 56 KB 👁 1 views

The study by Okishiro et al 1 concludes that the cytochrome P450 (CYP) genotype CYP2D6\*10/\*10 is unlikely to have a clinically significant impact on prognosis in women with breast cancer who receive adjuvant tamoxifen. However, several aspects of the study by Okishiro et al call their conclusions